Cepheid (CPHD) 43.47 $CPHD
Shares of CPHD Down 14.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu May 08, 11:09AM CDT
SmarTrend identified a Downtrend for Cepheid (NASDAQ:CPHD) on April 4th, 2014 at $49.87. In approximately 1 month, Cepheid has returned 14.06% as of today's recent price of $42.86.
Analysis of Automated Microbiology Instrumentation and Strategic Profiles of Leading Suppliers
M2 - Wed May 07, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c9zbx3/analysis_of) has announced the addition of the "Analysis of Automated Microbiology Instrumentation and Strategic Profiles of Leading Suppliers" report to their offering. This new 148-page report reviews current instrumentation technologies, and profiles features of leading automated and semi-automated Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic analyzers. The report also presents strategic assessments of current and emerging suppliers of microbiology products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests. The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon. Key Topics Covered: Introduction 1. Major Factors Affecting Market Penetration of Microbiology Instrumentation 2. Traditional Practices 3. Technological Challenges 4. Automation: Impact on the Microbiology Laboratory and the Patient Major Microbiology Automated and Semiautomated Systems 1. Multiple Purpose Microbiology Systems 2. Specialized Microbiology Systems 3. Molecular Diagnostic Systems 4. Immunodiagnostic Systems Companies Mentioned: - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - Biokit - Biotest - Caliper - Cepheid - Decode - DiaSorin - Diadexus - Diamedix - Eiken Chemical - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Hologic/Gen-Probe - ID Biomedical/GSK - Illumina - Kreatech - Li-Cor Biosciences - Life Technology - Lonza - Monogram Biosciences - Myriad Genetics - Nanogen/Elitech - Novartis Diagnostics/Grifols - Orchid CellMark - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - SeraCare - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan - Thermo Fisher - Wako - Wallac/PE - bioMerieux For more information visit http://www.researchandmarkets.com/research/c9...nalysis_of
Enteric Diseases in Germany 2014: Market Outlook and Emerging Opportunities
M2 - Wed May 07, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwhxpk/enteric_diseases) has announced the addition of the "Enteric Diseases in Germany 2014: Market Outlook and Emerging Opportunities" report to their offering. This new 322-page report presents detailed analysis of the German Enteric Diseases market, including sales forecasts and supplier shares for Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio and Yersinia. The report provides test volume and sales projections for Hospitals and Commercial/Private Labs. In addition to market share and sales forecasts, the report: - Examines market applications of Molecular Diagnostics, Monoclonal Antibodies, Immunoassays, IT and other emerging technologies; - Reviews features and operating characteristics of major analyzers used for microbiology testing; - Profiles key suppliers and potential market entrants developing innovative technologies and products; and - Analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and strategic planning issues. Methodology The report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products. In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer product and financial literature, as well as the author's proprietary data files was conducted. Key Topics Covered: I. Introduction II. Worldwide Market and Technology Overview A. Major Infectious Disease Tests B. Instrumentation Review of Leading Analyzers Marketed By Abbott, Beckman Coulter/Danaher, BioMerieux, OrthoClinical Diagnostics, Roche, Siemens, Tosoh, Wallac and Other Suppliers C. Emerging Diagnostic Technologies III. Germany: Market Size, Growth and Major Suppliers' Sales and Market Shares Alternative Market Penetration Strategies A. Internal Development B. Collaborative Arrangements C. University Contracts D. Distribution Strategies for Decentralized Testing Markets Potential Market Entry Barriers and Risks A. Market Maturity B. Cost Containment C. Competition D. Technological Edge and Limitations E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges Competitive Assessments: - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - BioRad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Enzo Biochem - Fujirebio - GenProbe - Hologic - ID Biomedical Innogenetics/Solvay - Kreatech - Life Technology - Lonza - Nanogen/Elitech - Novartis Diagnostics - OrthoClinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher - Wallac - Wako For more information visit http://www.researchandmarkets.com/research/mw...c_diseases
United States Molecular Diagnostics Market, Test Volume Forecast & Companies Report 2014-2018
M2 - Tue May 06, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8kwhmq/united_states) has announced the addition of the "United States (USA)-Molecular Diagnostics Market, Test Volume Forecast & Companies" report to their offering. United States Molecular Diagnostics Market & Future Forecast to 2018 Overview Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being added continuously. Molecular diagnostics is the promising area which can transform disease diagnosis, as diagnosis based on symptoms and use of surrogate markers is replaced by genomic and proteomic analysis. This fundamental shift offers the promise for early disease detection, potentially before symptoms have even occurred. United States molecular diagnostic market for 2018 is anticipated to more than double from its current value in 2013. In United States molecular diagnostic market, infectious disease controls the highest market share in 2013. But in terms of test volume food pathogen testing takes the lead pushing infectious disease at number two position. Molecular oncology tests have emerged as a significant rapidly growing market segment. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. United States constitutes the largest regional market for blood screening and blood products. Molecular diagnostics is also starting to emerge as an important tool for HLA Testing, Food Pathogen Detection Testing and other disease areas. In companies market share Hologic Inc., Myriad Genetics and Becton Dickinson together these 3 companies control more than 50% market share for 2013. However Becton Dickinson is expected to lose its market share gradually and Roche is expected to take its place by 2018. United States Molecular Diagnostics Market & Test Volume - Application Segment Analysis (2010 - 2018) 1. Oncology Testing 2. Infectious Diseases 3. Genetic Testing 4. Blood Screening 5. Food Pathogen Testing 6. Tissue Typing (HLA Testing) United States Molecular Diagnostics - Company Wise Sales Analysis (2010 - 2018) 1. Roche 2. Abbott 3. Myriad Genetics 4. BioMerieux 5. Qiagen 6. Hologic Inc. 7. Becton Dickinson 8. Siemens 9. Cepheid 10. Others Key Topics Covered: 1. Executive Summary 2. United States Molecular Diagnostics Market, Test Volume & Forecast (2010 - 2018) 3. United States Molecular Diagnostics Market & Volume Share (2010 - 2018) 4. United States Molecular Diagnostics Market & Forecast - Application Wise 5. United States Molecular Diagnostics Test Volume - Application Wise 6. United States Molecular Diagnostics Market - Company Wise 7. United States Molecular Diagnostics Market - Driving Factors 8. United States Molecular Diagnostics Market - Challenges For more information visit http://www.researchandmarkets.com/research/8k...ted_states
Cepheid Shares Down 13.3% Since SmarTrend's Sell Call (CPHD)
Comtex SmarTrend(R) - Thu May 01, 9:56AM CDT
SmarTrend identified a Downtrend for Cepheid (NASDAQ:CPHD) on April 4th, 2014 at $49.87. In approximately 4 weeks, Cepheid has returned 13.28% as of today's recent price of $43.25.
Research and Markets: Global Molecular Diagnostics Market Overivew, Trends & Opportunities, 2019
Business Wire - Thu May 01, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/98wf35/molecular) has announced the addition of the "Global Molecular Diagnostics Market Overivew, Trends & Opportunities, 2019" report to their offering.
Global Molecular Diagnostics Market Overivew, Trends & Opportunities, 2019
M2 - Thu May 01, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/82dtrj/molecular) has announced the addition of the "Global Molecular Diagnostics Market Overivew, Trends & Opportunities, 2019" report to their offering. This market is poised to grow at a CAGR of 15.1% from 2013-2019.Key players of this market include Abbott Laboratories, Roche Diagnostics, Novartis Diagnostics, Hologic Gen-Probe, Qiagen, and Cepheid among others. The research report on molecular diagnostics provides detailed analysis of the global market and helps in understanding the driving forces responsible for its growth. The report discusses the molecular diagnostics market on the basis of different technologies and applications. The technology segment comprises polymerase chain reaction (PCR), transcription mediated amplification (TMA), hybridization technique, microarray, sequencing and others. The application segment is classified into infectious diseases, blood donor screening and genomics. The genomics segmented is further classified into genetic disorders, oncology, HLA testing and pharmacogenetics testing. The infectious diseases segment comprises market for HIV infections, HAI, HCV infections and others. Market size estimates and forecasts for the period 2011 to 2019 have been provided for each of the segments in terms of USD million using 2012 as the base year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has been provided along with market size estimations. The market has also been segmented geographically into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW), and respective market sizes and forecasts have been provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global molecular diagnostics market, and future opportunities has been provided in the market overview section. This section also features a detailed market attractiveness analysis and Porter's five forces analysis for the molecular diagnostics market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview - Rising incidence of cancer cases - Aging population - Increase in incidence of chronic diseases - Increasing awareness and acceptance of companion diagnostics and personalized medicines - Issues with reimbursement policies - Technological advancements - Tapping the emerging economies - Porter's Five Force Analysis: Global Molecular Diagnostics Market Chapter 4 Molecular Diagnostics Market, by Technology - Polymerase Chain Reaction (PCR) - Transcription Mediated Amplification (TMA) - Microarray - Hybridization (ISH and FISH) - Next-generation sequencing Chapter 5 Global Molecular Diagnostics Market, by Applications - Infectious Diseases - Virology - Global Virology - Human immunodeficiency virus (HIV) testing - Human papillomavirus (HPV) testing - Hepatitis C virus (HCV) testing - Others - Bacteriology - Hospital Acquired Infection (HAI) testing - Genomics - Blood Donor Screening Chapter 6 Global Molecular Diagnostics Market, by Geography Chapter 7 Global Molecular Diagnostics Market Share Analysis Chapter 8 Recommendations - Long term contracts with healthcare service providers - Investing in emerging economies such as China, India and Russia - Broadening of distribution network Chapter 9 Company Profiles - Abbott Laboratories - Becton Dickinson & Company - Bio-Rad - bioMerieux - Cepheid - Danaher Corporation (Beckman Coulter) - F. Hoffmann-La Roche Ltd. - Hologic, Inc. (Gen-Probe) - Myriad Genetics, Inc. - Novartis International AG - Qiagen - Quest Diagnostics, Inc. - Siemens AG - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/82dtrj/molecular
Financial Results, Deployments, Mobile App Updates, and Upcoming Investor Conferences - Analyst Notes on FLIR, Itron, Garmin, FEI and Cepheid
PR Newswire - Wed Apr 30, 7:14AM CDT
Today, Analysts Review released its analysts' notes regarding FLIR Systems, Inc. (NASDAQ: FLIR), Itron, Inc. (NASDAQ: ITRI), Garmin Ltd. (NASDAQ: GRMN), FEI Company (NASDAQ: FEIC) and Cepheid (NASDAQ: CPHD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1805-100free.
Cepheid to Webcast Upcoming Financial Presentations
PR Newswire - Tue Apr 29, 3:05PM CDT
Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via webcast.
Global Hospital Acquired Disease Testing Market 2013-2019: Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others
M2 - Tue Apr 29, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3dns5j/hospital_acquired) has announced the addition of the "Global Hospital Acquired Disease Testing Market 2013-2019: Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others" report to their offering. This report covers the market analysis for various diagnostic tests performed to detect hospital associated infections, also called as nosocomial infections. Morbidity rate of nosocomial infections is increasing rapidly worldwide,thereby driving the hospital associated infection (HAI) diagnostic market towards remarkable growth. The stakeholders for this study include manufacturers and providers of diagnostic solutions for nosocomial infections. The global hospital acquired disease testing market is categorized on the basis of infection types,i.e., urinary tract infection, surgical site infection, pneumonia,blood stream infection, MRSA infection and others. A detailed market analysis and forecast for these segments has been provided in this study, in terms of market revenue (USD million) for the period 2011 to 2019.The report also provides the compounded annual growth rate (CAGR %) for each infection type for the forecast period 2013 to 2019, while market size estimations have been made considering 2012 as the base year. In terms of geographical distribution, the global hospital acquired disease testing market has been classified into four geographical areas, namely North America, Europe, Asia-Pacific and Rest of the World (RoW). The current and future market sizes (in terms of USD million) of the above regional markets have been provided in the report for the period 2011 to 2019 with their growth rate (%) for the period 2013 to 2019. The study further offers recommendations and highlights of the market, which would be useful for the current and future market players to sustain and grow in the global hospital acquired disease testing market. The market overview section of the report demonstrates the market dynamics and market trends such as the drivers, restraints and opportunities that influence the current nature and future status of this field. Impact factors such as market attractiveness analysis and Porter's five forces analysis have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the global hospital acquired disease testing market. This report concludes with the company profiles section which includes key information about the major players in this market. Some of the key players profiled in this report include Diatherix Laboratories Inc., Gen-Probe Inc., Qiagen GmbH, L Hoffman La Roche,Cepheid, Inc., Life Technologies Corporation, Meridian Biosciences, Cantel Medical Corporation, Nordion, Inc.and others. Key Topics Covered: - Introduction - Executive Summary - Market Overview - Global Hospital Acquired Disease Testing, by Infection Type - Global Hospital Acquired Disease Testing, by Geography - Recommendations - Company Profiles - Abbott Laboratories, Inc. - Alere, Inc. - bioMerieux, Inc. - Becton, Dickinson and Company - Cantel Medical Corporation - Cepheid, Inc. - Diatherix Laboratories Inc. - F. Hoffman-La Roche, Ltd. - Gen-Probe, Inc. - Life Technologies Corporation - Meridian Bioscience, Inc. - Nordion, Inc. - Qiagen GmbH For more information visit http://www.researchandmarkets.com/research/3d...l_acquired
Research and Markets: Global Enteric Disease Testing Market 2014-2018: Alere, bioMrieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market
Business Wire - Mon Apr 28, 3:36PM CDT
Research and Markets (http://www.researchandmarkets.com/research/v39rhj/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018: Alere, bioMerieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market" report to their offering.
Global Enteric Disease Testing Market 2014-2018: Alere, bioMerieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market
M2 - Mon Apr 28, 11:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s27mxj/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018: Alere, bioM?rieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market" report to their offering. One of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. The discovery and characterization of new emerging viruses and bacteria is playing an important role in the Diagnostics industry. Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. Further, the report states that one of the major challenges in the market is the presence of stringent regulatory approval processes for clinical in-vitro diagnostic tests for enteric disease identification. Key vendors dominating this space are: - Alere Inc - bioM?rieux SA - Bio-Rad Laboratories Inc. - Cepheid Inc. - DiaSorin S.p.A. Other vendors mentioned in the report are: - Affymetrix Inc. - Beckton, Dickenson and Co - Biomerica Inc - Coris BioConcept - Danaher Corp. - Meridian Bioscience Inc. - Quest Diagnostics Inc. - R-Biopharm AG - Trinity Biotech PLC. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Type of Diseases - Types of Clinical Diagnostic Testing - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s2...al_enteric
CPHD Crosses Below Key Moving Average Level
MarketNewsVideo.com - Thu Apr 24, 11:11AM CDT
In trading on Thursday, shares of Cepheid crossed below their 200 day moving average of $43.63, changing hands as low as $42.60 per share. Cepheid shares are currently trading off about 0.8% on the day.
Cepheid Has Returned 13.1% Since SmarTrend Recommendation (CPHD)
Comtex SmarTrend(R) - Thu Apr 24, 9:26AM CDT
SmarTrend identified a Downtrend for Cepheid (NASDAQ:CPHD) on April 4th, 2014 at $49.87. In approximately 3 weeks, Cepheid has returned 13.09% as of today's recent price of $43.34.
Japan Molecular Blood Typing, Grouping and Infectious Disease NAT Market 2014-2019
M2 - Tue Apr 22, 9:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3sfbk2/2014_japan) has announced the addition of the "2014 Japan Molecular Blood Typing, Grouping and Infectious Disease NAT Market: Emerging Technologies, Sales Forecasts, Supplier Shares, Competitive Strategies" report to their offering. This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the Japanese molecular blood banking market during the next five years, and assist industry executives in developing effective business, new product development and marketing strategies. The report explores future marketing and technological trends in Japan; provides test volume and sales forecasts by market segment/test location; compares features of major automated and semi-automated analyzers; profiles leading and emerging competitors; and identifies specific product and market opportunities facing suppliers during the next five years. Blood Group Genotyping PCR, PCR-RFLP, AS-PCR or PCR-SSP, Multiplex PCR, Real Time PCR, Sanger DNA Sequencing, Pyrosequencing Microarrays BeadChip Array, BloodChip, Genome Lab SNP Stream, Fluidic Microarray Systems, TaqMan OpenArray, MALDI-TOF-MS, Mini-Sequencing Blood Typing and Grouping Tests ABO, Antibody Panels, Antibody Screening/Indirect Antiglobulin, Antigen Typing (C, c, Duffy, E, e, I, i, Kell, Kidd, Le a, b, MN, P, S, s), Antiglobulin (Direct, C3 IgG, IgG, C3), Crossmatching (Immediate Spin, Full Crossmatch), Rh (D, Du). Infectious Disease Screening Tests AIDS (HIV NAT, HIV-1/2), Cytomegalovirus, Hepatitis (HAV NAT, HBV NAT, HBs Ag, Anti-HBc, HCV NAT, HCV, ALT/SGPT), HTLV-I/II, Parvovirus B19 NAT, Syphilis, West Nile Virus NAT Key Topics Covered: I. Introduction II. Worldwide Technology and Market Overview III. Japan IV. Major Product Development Opportunities V. Alternative Market Penetration Strategies VI. Potential Market Entry Barriers and Risks VII. Competitive Assessments Companies Mentioned - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - BioMerieux - Cepheid - Curtis Unyvero - Gen-Probe/Hologic - GenMark - Grifols - HTG - Immucor - Life Technologies - Nanosphere - Ortho-Clinical Diagnostics - Qiagen - Roche - Sarstedt - Siemens - Tecan For more information visit http://www.researchandmarkets.com/research/3sfbk2/2014_japan
Company News for April 22, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 9:06AM CDT
Companies in the News are: AMD,ATHN,ASBC,CPHD
Conference Call Schedules, New Diagnostic Tests, Senior-Level Appointments, and Acquisitions - Analyst Notes on Waters, Cepheid, Curtis-Wright, Trimble, and Cognex
PR Newswire - Tue Apr 22, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Waters Corp. (NYSE: WAT), Cepheid (NASDAQ: CPHD), Curtiss-Wright Corp. (NYSE: CW), Trimble Navigation Limited (NASDAQ: TRMB) Cognex Corporation (NASDAQ: CGNX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1198-100free
UK Molecular Blood Typing, Grouping and Infectious Disease NAT Market 2014-2019
M2 - Tue Apr 22, 6:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ncptd6/2014_uk_molecular) has announced the addition of the "2014 UK Molecular Blood Typing, Grouping and Infectious Disease NAT Market: Emerging Technologies, Sales Forecasts, Supplier Shares, Competitive Strategies" report to their offering. This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the UK molecular blood banking market during the next five years, and assist industry executives in developing effective business, new product development and marketing strategies. The report explores future marketing and technological trends in UK; provides test volume and sales forecasts by market segment/test location; compares features of major automated and semi-automated analyzers; profiles leading and emerging competitors; and identifies specific product and market opportunities facing suppliers during the next five years. Key Topics Covered: I. Introduction II. Worldwide Technology and Market Overview III. U.K. IV. Major Product Development Opportunities V. Alternative Market Penetration Strategies VI. Potential Market Entry Barriers and Risks VII. Competitive Assessments Companies Mentioned - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - BioMerieux - Cepheid - Curtis Unyvero - Gen-Probe/Hologic - GenMark - Grifols - HTG - Immucor - Life Technologies - Nanosphere - Ortho-Clinical Diagnostics - Qiagen - Roche - Sarstedt - Siemens - Tecan For more information visit http://www.researchandmarkets.com/research/nc..._molecular
Look for Shares of Cepheid to Potentially Rebound after Yesterday's 4.36% Sell Off
Comtex SmarTrend(R) - Mon Apr 21, 5:40PM CDT
Cepheid (NASDAQ:CPHD) traded in a range yesterday that spanned from a low of $44.30 to a high of $49.89. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $44.78 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Narrower-than-Expected Loss at Cepheid, View Tweaked - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 12:04PM CDT
Cepheid (CPHD) reported a loss of 10 cents per share in the first quarter of 2014, a substantial decrease from the year-ago income of 2 cents a share.
Shares of CPHD Down 14.1% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Thu May 08, 11:09AM CDT
SmarTrend identified a Downtrend for Cepheid (NASDAQ:CPHD) on April 4th, 2014 at $49.87. In approximately 1 month, Cepheid has returned 14.06% as of today's recent price of $42.86.
Analysis of Automated Microbiology Instrumentation and Strategic Profiles of Leading Suppliers
M2 - Wed May 07, 4:01AM CDT
Research and Markets (http://www.researchandmarkets.com/research/c9zbx3/analysis_of) has announced the addition of the "Analysis of Automated Microbiology Instrumentation and Strategic Profiles of Leading Suppliers" report to their offering. This new 148-page report reviews current instrumentation technologies, and profiles features of leading automated and semi-automated Molecular Diagnostic, Microbial Identification, Antibiotic Susceptibility, Blood Culture, Urine Screening, and Immunodiagnostic analyzers. The report also presents strategic assessments of current and emerging suppliers of microbiology products, including their sales, product portfolios, marketing tactics, technological know-how, new products in R&D, collaborative arrangements, and business strategies. The level of automation in the microbiology laboratory has been lagging behind that of other major clinical laboratory segments, such as chemistry and hematology. The slow acceptance of the technology is in part due to the complexity of developing automation suitable for microbiology tests. The introduction of automated microbiology instrumentation has been delayed by a number of intrinsic and technical problems. The diffusion of automated microbiology systems, once the technology was developed, has not matched that of other automated laboratory technologies. The acquisition of automation in microbiology has been slowed by forces less easily identifiable than the effects of various reimbursement plans. Some laboratorians still believe that current instrumentation is not the ultimate technology and expect better automation on the horizon. Key Topics Covered: Introduction 1. Major Factors Affecting Market Penetration of Microbiology Instrumentation 2. Traditional Practices 3. Technological Challenges 4. Automation: Impact on the Microbiology Laboratory and the Patient Major Microbiology Automated and Semiautomated Systems 1. Multiple Purpose Microbiology Systems 2. Specialized Microbiology Systems 3. Molecular Diagnostic Systems 4. Immunodiagnostic Systems Companies Mentioned: - Abbott - Affymetrix - Agilent Technologies - Applied Gene Technologies - Arca/Nuvelo - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - Biokit - Biotest - Caliper - Cepheid - Decode - DiaSorin - Diadexus - Diamedix - Eiken Chemical - Enzo Biochem - Exact Sciences - Fujirebio/Innogenetics - Hologic/Gen-Probe - ID Biomedical/GSK - Illumina - Kreatech - Li-Cor Biosciences - Life Technology - Lonza - Monogram Biosciences - Myriad Genetics - Nanogen/Elitech - Novartis Diagnostics/Grifols - Orchid CellMark - Ortho-Clinical Diagnostics - Proteome Sciences - Qiagen - Roche - Scienion - Sequenom - SeraCare - Shimadzu - Siemens - Sierra Molecular - Takara Bio - Tecan - Thermo Fisher - Wako - Wallac/PE - bioMerieux For more information visit http://www.researchandmarkets.com/research/c9...nalysis_of
Enteric Diseases in Germany 2014: Market Outlook and Emerging Opportunities
M2 - Wed May 07, 3:33AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mwhxpk/enteric_diseases) has announced the addition of the "Enteric Diseases in Germany 2014: Market Outlook and Emerging Opportunities" report to their offering. This new 322-page report presents detailed analysis of the German Enteric Diseases market, including sales forecasts and supplier shares for Campylobacter, Cryptosporidium, E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, Shigella, Vibrio and Yersinia. The report provides test volume and sales projections for Hospitals and Commercial/Private Labs. In addition to market share and sales forecasts, the report: - Examines market applications of Molecular Diagnostics, Monoclonal Antibodies, Immunoassays, IT and other emerging technologies; - Reviews features and operating characteristics of major analyzers used for microbiology testing; - Profiles key suppliers and potential market entrants developing innovative technologies and products; and - Analyzes emerging opportunities, alternative market penetration strategies, market entry barriers/risks, and strategic planning issues. Methodology The report is based on a combination of primary and secondary information sources, including interviews with laboratory directors, and executives of leading diagnostics companies and start-up firms developing innovative products. In addition to primary sources of information, a comprehensive review of the most recent technical and business publications, manufacturer product and financial literature, as well as the author's proprietary data files was conducted. Key Topics Covered: I. Introduction II. Worldwide Market and Technology Overview A. Major Infectious Disease Tests B. Instrumentation Review of Leading Analyzers Marketed By Abbott, Beckman Coulter/Danaher, BioMerieux, OrthoClinical Diagnostics, Roche, Siemens, Tosoh, Wallac and Other Suppliers C. Emerging Diagnostic Technologies III. Germany: Market Size, Growth and Major Suppliers' Sales and Market Shares Alternative Market Penetration Strategies A. Internal Development B. Collaborative Arrangements C. University Contracts D. Distribution Strategies for Decentralized Testing Markets Potential Market Entry Barriers and Risks A. Market Maturity B. Cost Containment C. Competition D. Technological Edge and Limitations E. Patent Protection F. Regulatory Constraints G. Decentralized Testing Market Challenges Competitive Assessments: - Abbott - Affymetrix - Beckman Coulter/Danaher - Becton Dickinson - bioMerieux - BioRad - Cepheid - Diamedix - DiaSorin - Eiken Chemical - Enzo Biochem - Fujirebio - GenProbe - Hologic - ID Biomedical Innogenetics/Solvay - Kreatech - Life Technology - Lonza - Nanogen/Elitech - Novartis Diagnostics - OrthoClinical Diagnostics - Qiagen - Roche - Scienion - Sequenom - SeraCare - Siemens - Takara Bio - Thermo Fisher - Wallac - Wako For more information visit http://www.researchandmarkets.com/research/mw...c_diseases
United States Molecular Diagnostics Market, Test Volume Forecast & Companies Report 2014-2018
M2 - Tue May 06, 5:13AM CDT
Research and Markets (http://www.researchandmarkets.com/research/8kwhmq/united_states) has announced the addition of the "United States (USA)-Molecular Diagnostics Market, Test Volume Forecast & Companies" report to their offering. United States Molecular Diagnostics Market & Future Forecast to 2018 Overview Molecular diagnostics is a rapidly-advancing area of research and medicine, with new technologies and applications being added continuously. Molecular diagnostics is the promising area which can transform disease diagnosis, as diagnosis based on symptoms and use of surrogate markers is replaced by genomic and proteomic analysis. This fundamental shift offers the promise for early disease detection, potentially before symptoms have even occurred. United States molecular diagnostic market for 2018 is anticipated to more than double from its current value in 2013. In United States molecular diagnostic market, infectious disease controls the highest market share in 2013. But in terms of test volume food pathogen testing takes the lead pushing infectious disease at number two position. Molecular oncology tests have emerged as a significant rapidly growing market segment. In the current medical diagnostics market, molecular diagnostics for cancer testing offers one of the brightest areas for growth and innovation. United States constitutes the largest regional market for blood screening and blood products. Molecular diagnostics is also starting to emerge as an important tool for HLA Testing, Food Pathogen Detection Testing and other disease areas. In companies market share Hologic Inc., Myriad Genetics and Becton Dickinson together these 3 companies control more than 50% market share for 2013. However Becton Dickinson is expected to lose its market share gradually and Roche is expected to take its place by 2018. United States Molecular Diagnostics Market & Test Volume - Application Segment Analysis (2010 - 2018) 1. Oncology Testing 2. Infectious Diseases 3. Genetic Testing 4. Blood Screening 5. Food Pathogen Testing 6. Tissue Typing (HLA Testing) United States Molecular Diagnostics - Company Wise Sales Analysis (2010 - 2018) 1. Roche 2. Abbott 3. Myriad Genetics 4. BioMerieux 5. Qiagen 6. Hologic Inc. 7. Becton Dickinson 8. Siemens 9. Cepheid 10. Others Key Topics Covered: 1. Executive Summary 2. United States Molecular Diagnostics Market, Test Volume & Forecast (2010 - 2018) 3. United States Molecular Diagnostics Market & Volume Share (2010 - 2018) 4. United States Molecular Diagnostics Market & Forecast - Application Wise 5. United States Molecular Diagnostics Test Volume - Application Wise 6. United States Molecular Diagnostics Market - Company Wise 7. United States Molecular Diagnostics Market - Driving Factors 8. United States Molecular Diagnostics Market - Challenges For more information visit http://www.researchandmarkets.com/research/8k...ted_states
Cepheid Shares Down 13.3% Since SmarTrend's Sell Call (CPHD)
Comtex SmarTrend(R) - Thu May 01, 9:56AM CDT
SmarTrend identified a Downtrend for Cepheid (NASDAQ:CPHD) on April 4th, 2014 at $49.87. In approximately 4 weeks, Cepheid has returned 13.28% as of today's recent price of $43.25.
Research and Markets: Global Molecular Diagnostics Market Overivew, Trends & Opportunities, 2019
Business Wire - Thu May 01, 4:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/98wf35/molecular) has announced the addition of the "Global Molecular Diagnostics Market Overivew, Trends & Opportunities, 2019" report to their offering.
Global Molecular Diagnostics Market Overivew, Trends & Opportunities, 2019
M2 - Thu May 01, 3:32AM CDT
Research and Markets (http://www.researchandmarkets.com/research/82dtrj/molecular) has announced the addition of the "Global Molecular Diagnostics Market Overivew, Trends & Opportunities, 2019" report to their offering. This market is poised to grow at a CAGR of 15.1% from 2013-2019.Key players of this market include Abbott Laboratories, Roche Diagnostics, Novartis Diagnostics, Hologic Gen-Probe, Qiagen, and Cepheid among others. The research report on molecular diagnostics provides detailed analysis of the global market and helps in understanding the driving forces responsible for its growth. The report discusses the molecular diagnostics market on the basis of different technologies and applications. The technology segment comprises polymerase chain reaction (PCR), transcription mediated amplification (TMA), hybridization technique, microarray, sequencing and others. The application segment is classified into infectious diseases, blood donor screening and genomics. The genomics segmented is further classified into genetic disorders, oncology, HLA testing and pharmacogenetics testing. The infectious diseases segment comprises market for HIV infections, HAI, HCV infections and others. Market size estimates and forecasts for the period 2011 to 2019 have been provided for each of the segments in terms of USD million using 2012 as the base year. The CAGR (%) of each market segment for the forecast period 2013 to 2019 has been provided along with market size estimations. The market has also been segmented geographically into four regions: North America, Europe, Asia Pacific and Rest of the World (RoW), and respective market sizes and forecasts have been provided for each of these regions. A detailed qualitative analysis of the factors responsible for driving and restraining the growth of the global molecular diagnostics market, and future opportunities has been provided in the market overview section. This section also features a detailed market attractiveness analysis and Porter's five forces analysis for the molecular diagnostics market. Key Topics Covered: Chapter 1 Preface Chapter 2 Executive Summary Chapter 3 Market Overview - Rising incidence of cancer cases - Aging population - Increase in incidence of chronic diseases - Increasing awareness and acceptance of companion diagnostics and personalized medicines - Issues with reimbursement policies - Technological advancements - Tapping the emerging economies - Porter's Five Force Analysis: Global Molecular Diagnostics Market Chapter 4 Molecular Diagnostics Market, by Technology - Polymerase Chain Reaction (PCR) - Transcription Mediated Amplification (TMA) - Microarray - Hybridization (ISH and FISH) - Next-generation sequencing Chapter 5 Global Molecular Diagnostics Market, by Applications - Infectious Diseases - Virology - Global Virology - Human immunodeficiency virus (HIV) testing - Human papillomavirus (HPV) testing - Hepatitis C virus (HCV) testing - Others - Bacteriology - Hospital Acquired Infection (HAI) testing - Genomics - Blood Donor Screening Chapter 6 Global Molecular Diagnostics Market, by Geography Chapter 7 Global Molecular Diagnostics Market Share Analysis Chapter 8 Recommendations - Long term contracts with healthcare service providers - Investing in emerging economies such as China, India and Russia - Broadening of distribution network Chapter 9 Company Profiles - Abbott Laboratories - Becton Dickinson & Company - Bio-Rad - bioMerieux - Cepheid - Danaher Corporation (Beckman Coulter) - F. Hoffmann-La Roche Ltd. - Hologic, Inc. (Gen-Probe) - Myriad Genetics, Inc. - Novartis International AG - Qiagen - Quest Diagnostics, Inc. - Siemens AG - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/82dtrj/molecular
Financial Results, Deployments, Mobile App Updates, and Upcoming Investor Conferences - Analyst Notes on FLIR, Itron, Garmin, FEI and Cepheid
PR Newswire - Wed Apr 30, 7:14AM CDT
Today, Analysts Review released its analysts' notes regarding FLIR Systems, Inc. (NASDAQ: FLIR), Itron, Inc. (NASDAQ: ITRI), Garmin Ltd. (NASDAQ: GRMN), FEI Company (NASDAQ: FEIC) and Cepheid (NASDAQ: CPHD). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1805-100free.
Cepheid to Webcast Upcoming Financial Presentations
PR Newswire - Tue Apr 29, 3:05PM CDT
Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via webcast.
Global Hospital Acquired Disease Testing Market 2013-2019: Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others
M2 - Tue Apr 29, 3:49AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3dns5j/hospital_acquired) has announced the addition of the "Global Hospital Acquired Disease Testing Market 2013-2019: Pneumonia, UTI, Blood Stream, Surgical Site, MRSA Infection, and Others" report to their offering. This report covers the market analysis for various diagnostic tests performed to detect hospital associated infections, also called as nosocomial infections. Morbidity rate of nosocomial infections is increasing rapidly worldwide,thereby driving the hospital associated infection (HAI) diagnostic market towards remarkable growth. The stakeholders for this study include manufacturers and providers of diagnostic solutions for nosocomial infections. The global hospital acquired disease testing market is categorized on the basis of infection types,i.e., urinary tract infection, surgical site infection, pneumonia,blood stream infection, MRSA infection and others. A detailed market analysis and forecast for these segments has been provided in this study, in terms of market revenue (USD million) for the period 2011 to 2019.The report also provides the compounded annual growth rate (CAGR %) for each infection type for the forecast period 2013 to 2019, while market size estimations have been made considering 2012 as the base year. In terms of geographical distribution, the global hospital acquired disease testing market has been classified into four geographical areas, namely North America, Europe, Asia-Pacific and Rest of the World (RoW). The current and future market sizes (in terms of USD million) of the above regional markets have been provided in the report for the period 2011 to 2019 with their growth rate (%) for the period 2013 to 2019. The study further offers recommendations and highlights of the market, which would be useful for the current and future market players to sustain and grow in the global hospital acquired disease testing market. The market overview section of the report demonstrates the market dynamics and market trends such as the drivers, restraints and opportunities that influence the current nature and future status of this field. Impact factors such as market attractiveness analysis and Porter's five forces analysis have also been explained in the market overview section of the report, in order to give a thorough analysis of the overall competitive scenario in the global hospital acquired disease testing market. This report concludes with the company profiles section which includes key information about the major players in this market. Some of the key players profiled in this report include Diatherix Laboratories Inc., Gen-Probe Inc., Qiagen GmbH, L Hoffman La Roche,Cepheid, Inc., Life Technologies Corporation, Meridian Biosciences, Cantel Medical Corporation, Nordion, Inc.and others. Key Topics Covered: - Introduction - Executive Summary - Market Overview - Global Hospital Acquired Disease Testing, by Infection Type - Global Hospital Acquired Disease Testing, by Geography - Recommendations - Company Profiles - Abbott Laboratories, Inc. - Alere, Inc. - bioMerieux, Inc. - Becton, Dickinson and Company - Cantel Medical Corporation - Cepheid, Inc. - Diatherix Laboratories Inc. - F. Hoffman-La Roche, Ltd. - Gen-Probe, Inc. - Life Technologies Corporation - Meridian Bioscience, Inc. - Nordion, Inc. - Qiagen GmbH For more information visit http://www.researchandmarkets.com/research/3d...l_acquired
Research and Markets: Global Enteric Disease Testing Market 2014-2018: Alere, bioMrieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market
Business Wire - Mon Apr 28, 3:36PM CDT
Research and Markets (http://www.researchandmarkets.com/research/v39rhj/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018: Alere, bioMerieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market" report to their offering.
Global Enteric Disease Testing Market 2014-2018: Alere, bioMerieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market
M2 - Mon Apr 28, 11:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s27mxj/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018: Alere, bioM?rieux, Bio-Rad Laboratories, Cepheid & DiaSorin Dominate the Market" report to their offering. One of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. The discovery and characterization of new emerging viruses and bacteria is playing an important role in the Diagnostics industry. Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. Further, the report states that one of the major challenges in the market is the presence of stringent regulatory approval processes for clinical in-vitro diagnostic tests for enteric disease identification. Key vendors dominating this space are: - Alere Inc - bioM?rieux SA - Bio-Rad Laboratories Inc. - Cepheid Inc. - DiaSorin S.p.A. Other vendors mentioned in the report are: - Affymetrix Inc. - Beckton, Dickenson and Co - Biomerica Inc - Coris BioConcept - Danaher Corp. - Meridian Bioscience Inc. - Quest Diagnostics Inc. - R-Biopharm AG - Trinity Biotech PLC. Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Type of Diseases - Types of Clinical Diagnostic Testing - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/s2...al_enteric
CPHD Crosses Below Key Moving Average Level
MarketNewsVideo.com - Thu Apr 24, 11:11AM CDT
In trading on Thursday, shares of Cepheid crossed below their 200 day moving average of $43.63, changing hands as low as $42.60 per share. Cepheid shares are currently trading off about 0.8% on the day.
Cepheid Has Returned 13.1% Since SmarTrend Recommendation (CPHD)
Comtex SmarTrend(R) - Thu Apr 24, 9:26AM CDT
SmarTrend identified a Downtrend for Cepheid (NASDAQ:CPHD) on April 4th, 2014 at $49.87. In approximately 3 weeks, Cepheid has returned 13.09% as of today's recent price of $43.34.
Japan Molecular Blood Typing, Grouping and Infectious Disease NAT Market 2014-2019
M2 - Tue Apr 22, 9:26AM CDT
Research and Markets (http://www.researchandmarkets.com/research/3sfbk2/2014_japan) has announced the addition of the "2014 Japan Molecular Blood Typing, Grouping and Infectious Disease NAT Market: Emerging Technologies, Sales Forecasts, Supplier Shares, Competitive Strategies" report to their offering. This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the Japanese molecular blood banking market during the next five years, and assist industry executives in developing effective business, new product development and marketing strategies. The report explores future marketing and technological trends in Japan; provides test volume and sales forecasts by market segment/test location; compares features of major automated and semi-automated analyzers; profiles leading and emerging competitors; and identifies specific product and market opportunities facing suppliers during the next five years. Blood Group Genotyping PCR, PCR-RFLP, AS-PCR or PCR-SSP, Multiplex PCR, Real Time PCR, Sanger DNA Sequencing, Pyrosequencing Microarrays BeadChip Array, BloodChip, Genome Lab SNP Stream, Fluidic Microarray Systems, TaqMan OpenArray, MALDI-TOF-MS, Mini-Sequencing Blood Typing and Grouping Tests ABO, Antibody Panels, Antibody Screening/Indirect Antiglobulin, Antigen Typing (C, c, Duffy, E, e, I, i, Kell, Kidd, Le a, b, MN, P, S, s), Antiglobulin (Direct, C3 IgG, IgG, C3), Crossmatching (Immediate Spin, Full Crossmatch), Rh (D, Du). Infectious Disease Screening Tests AIDS (HIV NAT, HIV-1/2), Cytomegalovirus, Hepatitis (HAV NAT, HBV NAT, HBs Ag, Anti-HBc, HCV NAT, HCV, ALT/SGPT), HTLV-I/II, Parvovirus B19 NAT, Syphilis, West Nile Virus NAT Key Topics Covered: I. Introduction II. Worldwide Technology and Market Overview III. Japan IV. Major Product Development Opportunities V. Alternative Market Penetration Strategies VI. Potential Market Entry Barriers and Risks VII. Competitive Assessments Companies Mentioned - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - BioMerieux - Cepheid - Curtis Unyvero - Gen-Probe/Hologic - GenMark - Grifols - HTG - Immucor - Life Technologies - Nanosphere - Ortho-Clinical Diagnostics - Qiagen - Roche - Sarstedt - Siemens - Tecan For more information visit http://www.researchandmarkets.com/research/3sfbk2/2014_japan
Company News for April 22, 2014 - Corporate Summary
Zacks Equity Research - Zacks Investment Research - Tue Apr 22, 9:06AM CDT
Companies in the News are: AMD,ATHN,ASBC,CPHD
Conference Call Schedules, New Diagnostic Tests, Senior-Level Appointments, and Acquisitions - Analyst Notes on Waters, Cepheid, Curtis-Wright, Trimble, and Cognex
PR Newswire - Tue Apr 22, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Waters Corp. (NYSE: WAT), Cepheid (NASDAQ: CPHD), Curtiss-Wright Corp. (NYSE: CW), Trimble Navigation Limited (NASDAQ: TRMB) Cognex Corporation (NASDAQ: CGNX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1198-100free
UK Molecular Blood Typing, Grouping and Infectious Disease NAT Market 2014-2019
M2 - Tue Apr 22, 6:36AM CDT
Research and Markets (http://www.researchandmarkets.com/research/ncptd6/2014_uk_molecular) has announced the addition of the "2014 UK Molecular Blood Typing, Grouping and Infectious Disease NAT Market: Emerging Technologies, Sales Forecasts, Supplier Shares, Competitive Strategies" report to their offering. This comprehensive report is designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities in the UK molecular blood banking market during the next five years, and assist industry executives in developing effective business, new product development and marketing strategies. The report explores future marketing and technological trends in UK; provides test volume and sales forecasts by market segment/test location; compares features of major automated and semi-automated analyzers; profiles leading and emerging competitors; and identifies specific product and market opportunities facing suppliers during the next five years. Key Topics Covered: I. Introduction II. Worldwide Technology and Market Overview III. U.K. IV. Major Product Development Opportunities V. Alternative Market Penetration Strategies VI. Potential Market Entry Barriers and Risks VII. Competitive Assessments Companies Mentioned - Abbott - Beckman Coulter/Danaher - Becton Dickinson - Bio-Rad - BioMerieux - Cepheid - Curtis Unyvero - Gen-Probe/Hologic - GenMark - Grifols - HTG - Immucor - Life Technologies - Nanosphere - Ortho-Clinical Diagnostics - Qiagen - Roche - Sarstedt - Siemens - Tecan For more information visit http://www.researchandmarkets.com/research/nc..._molecular
Look for Shares of Cepheid to Potentially Rebound after Yesterday's 4.36% Sell Off
Comtex SmarTrend(R) - Mon Apr 21, 5:40PM CDT
Cepheid (NASDAQ:CPHD) traded in a range yesterday that spanned from a low of $44.30 to a high of $49.89. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $44.78 on volume of 1.6 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Narrower-than-Expected Loss at Cepheid, View Tweaked - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 21, 12:04PM CDT
Cepheid (CPHD) reported a loss of 10 cents per share in the first quarter of 2014, a substantial decrease from the year-ago income of 2 cents a share.
